Impax Laboratories Inc (IPXL)

18.45
NASDAQ : Health Care
Prev Close 17.95
Day Low/High 17.76 / 19.20
52 Wk Low/High 7.75 / 27.29
Avg Volume 1.75M
Exchange NASDAQ
Shares Outstanding 74.31M
Market Cap 1.33B
EPS -6.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Teva's Massive Debt Load Just Became an Even Bigger Issue

Teva's Massive Debt Load Just Became an Even Bigger Issue

It is just not going to get better anytime soon.

Teva Shares Are Getting Obliterated Again After Vicious Investment Bank Downgrades

Teva Shares Are Getting Obliterated Again After Vicious Investment Bank Downgrades

Teva's stock is crumbling as another analyst slams it with a downgrade.

Teva Shares Are Taking a Beating and Dragging Down the Generic Drugmakers

Teva Shares Are Taking a Beating and Dragging Down the Generic Drugmakers

Teva said weak U.S. markets and the ongoing political turmoil in Venezuela weighed on the company's second quarter performance.

Biotech Movers: Impax Shares Jump on FDA Approval for Generic Version of Concerta

Biotech Movers: Impax Shares Jump on FDA Approval for Generic Version of Concerta

Impax Laboratories, Akebia Therapeutics and Alder BioPharmaceuticals were among the biotech movers in premarket trading on July 17.

Biotech Movers: Immuno-Oncology Pact With Celgene Sends BeiGene Shares Soaring

Biotech Movers: Immuno-Oncology Pact With Celgene Sends BeiGene Shares Soaring

BeiGene and Impax Laboratories were among the biotech movers in premarket trading on July 6.

Biotech Movers: Adamis Shares Jump After FDA Approves Epinephrine Pre-filled Syringe

Biotech Movers: Adamis Shares Jump After FDA Approves Epinephrine Pre-filled Syringe

Adamis Pharmaceuticals, Impax Laboratories and Accorda Therapeutics were among the biotech stock movers in premarket trading on June 16.

Drug Price Inflation and a Patent Cliff Could Trigger a Wave of Deals in Generic Drugs Space

Drug Price Inflation and a Patent Cliff Could Trigger a Wave of Deals in Generic Drugs Space

Generic drugmakers are likely to limit themselves to acquisitions of small- and mid-sized companies in the immediate future because of over-leveraging and turmoil in the executive ranks..

Depomed, Insys Shares Down After FDA Decision on Endo's Opana ER

Depomed, Insys Shares Down After FDA Decision on Endo's Opana ER

The FDA requested Endo to remove its opioid pain medication from the market, expressing concern that the "benefits of the drug may no longer outweigh its risks."

These Stocks Show Change of Direction

These Stocks Show Change of Direction

Finding bullish and bearish reversals in the market.

Generics Drop Across Board as DOJ Inquiry Expands

Generics Drop Across Board as DOJ Inquiry Expands

The addition of Perrigo to the list of generics makers under investigation is more bad news for a sector already under pressure from low prices.

Perrigo Stock Sliding on DOJ Search

Perrigo Stock Sliding on DOJ Search

The investigation is in relation to drug pricing in the pharmaceutical industry.

IPXL Crosses Above Average Analyst Target

In recent trading, shares of Impax Laboratories Inc have crossed above the average analyst 12-month target price of $12.00, changing hands for $12.70/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Impax Laboratories Stock Sees Short Interest Drop 32.3%

The most recent short interest data has been released for the 03/15/2017 settlement date, which shows a 1,670,394 share decrease in total short interest for Impax Laboratories Inc , to 3,500,878, a decrease of 32.30% since 02/28/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Impax Gains 38% On CEO Appointment, Talk of Sale

Impax Gains 38% On CEO Appointment, Talk of Sale

The company hired Paul Bisaro, former chairman at Allergan, to become CEO as Morgan Stanley helps explore alternatives, including a sale.

Skincare Makers Lead Biotech Movers

Skincare Makers Lead Biotech Movers

Paratek Pharmaceuticals soared while Foamix floundered ahead of market's open.

Impax Board Of Directors Appoints Paul M. Bisaro President And CEO

Industry Veteran Brings a Successful Record of Operational Execution, Driving Transformation and Delivering Growth

First Week Of IPXL May 19th Options Trading

Investors in Impax Laboratories Inc saw new options become available this week, for the May 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the IPXL options chain for the new May 19th contracts and identified one put and one call contract of particular interest.

Politicians Question EpiPen Competitor's High Pricetag

Politicians Question EpiPen Competitor's High Pricetag

Chuck Grassley is hammering the privately held drug company on its $4,500 EpiPen competitor.